Arrowhead Research announced that it has named David Lewis as its vice president of biology, and David Rozema as its vice president of chemistry.
Lewis and Rozema recently joined Arrowhead through the company's recent acquisition of Roche's Madison, Wis.-based RNA therapeutic operations (GSN 10/27/2011).
Lewis will oversee operations at the Madison facility and handle preclinical research and developments there. Rozema will supervise the development and synthesis of siRNA delivery vehicles.